

From: Howell, Kathy L
Sent: Wednesday, November 21, 2018 1:00 PM
To: Howell, Kathy L <Kathy.L.Howell@wv.gov>
Subject: Family Planning News Update
Importance: High

Good afternoon!

I just have a couple of things I need to bring to your attention. First, I want to remind everyone about the opportunity to receive technical assistance (TA) for participation in SBIRT! For those who don't know about SBIRT, here is some information about it:

Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based practice used to identify, reduce, and prevent problematic use, abuse, and dependence on alcohol and illicit drugs. The SBIRT model was incited by an Institute of Medicine recommendation that called for community-based screening for health risk behaviors, including substance use.

SBIRT CONSISTS OF THREE MAJOR COMPONENTS:

- **Screening** — a healthcare professional assesses a patient for risky substance use behaviors using standardized screening tools. Screening can occur in any healthcare setting
- **Brief Intervention** — a healthcare professional engages a patient showing risky substance use behaviors in a short conversation, providing feedback and advice
- **Referral to Treatment** — a healthcare professional provides a referral to brief therapy or additional treatment to patients who screen in need of additional services

We greatly encourage you take advantage of this free opportunity from the Office of Population Affairs personalized support to develop SBIRT at your site. The application is simple and super quick to complete. The deadline for applications is 12/5/18, so hurry and submit your application as soon as you can. [Click here](#) to get started and feel free to contact Dickie Lynn Gronseth (DickieLynn.Gronseth@hhs.gov) or Shelley Miller (smiller@danyainstitute.org) with any questions.

And the second thing I need to bring to your attention is the recent updates to prescribing information and patient information for Nexplanon. Last week, Merck issued a recent change to the prescribing information (PI) and patient information (PPI) for NEXPLANON (etonogestrel implant) 68 mg Radiopaque. Because the updates involve the insertion and removal procedures, it is important that you carefully review the updated Prescribing Information. See the details of the updates to the [PI \(PDF\)](#) and [PPI \(PDF\)](#). Accordingly, Merck has plans to update the required training module.

As always, if you have any questions or comments, please feel free to let me know. Have a Happy Thanksgiving!

Kathy Howell
West Virginia Department of Health and Human Resources
Family Planning Program
350 Capitol Street, Room 427
Charleston, WV 25301-3714
Phone: 304-356-4456
Fax: 304-957-7505
Kathy.L.Howell@wv.gov